In vivo and in vitro evidences of dehydroepiandrosterone protective role on the cardiovascular system

International Journal of Endocrinology and Metabolism

Volumn 13, Issue 2, 2015, Pages

  Mannic, Tiphaine ^a,b   Viguie, Joanna ^a   Rossier, Michel Florian ^a,c  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Service of Clinical Chemistry and Toxicology   (Switzerland)

Author keywords

Cardiovascular system; Dehydroepiandrosterone; Disease; Endothelium; Myocytes, cardiac; Steroids

Indexed keywords

PRASTERONE; PRASTERONE SULFATE;

AGING; ARTERIAL WALL THICKNESS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL;

EID: 84929009106     PISSN: 1726913X     EISSN: 17269148     Source Type: Journal    
DOI: 10.5812/ijem.24660     Document Type: Review

References (45)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21.
2. Weiss EP, Villareal DT, Ehsani AA, Fontana L, Holloszy JO. Dehydroepiandrosterone replacement therapy in older adults improves indices of arterial stiffness. Aging Cell. 2012;11(5):876-84.
3. Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochem Pharmacol. 2013;85(6):718-26.
4. Mazat L, Lafont S, Berr C, Debuire B, Tessier JF, Dartigues JF, et al. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci U S A. 2001;98(14):8145-50.
5. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol. 1999;39(4):327-48.
6. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315(24):1519-24.
7. Shufelt C, Bretsky P, Almeida CM, Johnson BD, Shaw LJ, Azziz postmenopausal women: results from the National Institutes of Health-National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010;95(11):4985-92.
8. Kedziora-Kornatowska K, Beszczynska-Oles R, Kornatowski T, Szadujkis-Szadurski L. The analysis of dehydroepiandrosterone sulphate concentration in elderly age women depending on coexisting disease states. Adv Med Sci. 2007;52 Suppl 1:126-30.
9. Haring R, Teng Z, Xanthakis V, Coviello A, Sullivan L, Bhasin S, et al. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol (Oxf). 2013;78(4):629-34.
10. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res. 2008;31(1):69-74.
11. Yoshida S, Aihara K, Azuma H, Uemoto R, Sumitomo-Ueda Y, Yagi S, et al. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. 2010;212(1):310-5.
12. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87(8):3632-9.
13. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Ann N Y Acad Sci. 1995;774:271-80.
14. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2001;153(1):79-89.
15. Jimenez MC, Sun Q, Schurks M, Chiuve S, Hu FB, Manson JE, et al. Low dehydroepiandrosterone sulfate is associated with increased risk of ischemic stroke among women. Stroke. 2013;44(7):1784-9.
16. Ravaglia G, Forti P, Maioli F, Sacchetti L, Nativio V, Scali CR, et al. Dehydroepiandrosterone-sulfate serum levels and common age-related diseases: results from a cross-sectional Italian study of a general elderly population. Exp Gerontol. 2002;37(5):701-12.
17. Liu L, Wang M, Yang X, Bi M, Na L, Niu Y, et al. Fasting serum lipid and dehydroepiandrosterone sulfate as important metabolites for detecting isolated postchallenge diabetes: serum metabolomics via ultra-high-performance LC-MS. Clin Chem. 2013;59(9):1338-48.
18. Suzuki T, Yano Y, Sakamoto M, Uemura M, Yasuma T, Onishi Y, et al. Correlation of circulating dehydroepiandrosterone with activated protein C generation and carotid intima-media thickness in male patients with type 2 diabetes. Diabet Med. 2012;29(7):e41-6.
19. Ponikowska B, Jankowska EA, Maj J, Wegrzynowska-Teodorczyk K, Biel B, Reczuch K, et al. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol. 2010;143(3):343-8.
20. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, et al. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation. 2009;120(13):1231-40.
21. Aragno M, Meineri G, Vercellinatto I, Bardini P, Raimondo S, Peiretti PG, et al. Cardiac impairment in rabbits fed a high-fat diet is counteracted by dehydroepiandrosterone supplementation. Life Sci. 2009;85(1-2):77-84.
22. Aragno M, Mastrocola R, Alloatti G, Vercellinatto I, Bardini P, Geuna S, et al. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology. 2008;149(1):380-8.
23. Aragno M, Mastrocola R, Medana C, Catalano MG, Vercellinatto I, Danni O, et al. Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology. 2006;147(12):5967-74.
24. Dumas de La Roque E, Bellance N, Rossignol R, Begueret H, Billaud M, dos Santos P, et al. Dehydroepiandrosterone reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats. Eur Respir J. 2012;40(6):1420-9.
25. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003;88(7):3190-5.
26. Williams MR, Dawood T, Ling S, Dai A, Lew R, Myles K, et al. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab. 2004;89(9):4708-15.
27. McHenry CM, Bell PM, Hunter SJ, Thompson CJ, Courtney CH, Ennis CN, et al. Effects of dehydroepiandrosterone sulphate (DHEAS) replacement on insulin action and quality of life in hypopituitary females: a double-blind, placebo-controlled study. Clin Endocrinol (Oxf). 2012;77(3):423-9.
28. Goel RM, Cappola AR. Dehydroepiandrosterone sulfate and postmenopausal women. Curr Opin Endocrinol Diabetes Obes. 2011;18(3):171-6.
29. Sahelian R, Borken S. Dehydroepiandrosterone and cardiac arrhythmia. Ann Intern Med. 1998;129(7):588.
30. Curatola AM, Huang K, Naftolin F. Dehydroepiandrosterone (DHEA) inhibition of monocyte binding by vascular endothelium is associated with sialylation of neural cell adhesion molecule. Reprod Sci. 2012;19(1):86-91.
31. Gutierrez G, Mendoza C, Zapata E, Montiel A, Reyes E, Montano LF, et al. Dehydroepiandrosterone inhibits the TNF-alpha-induced inflammatory response in human umbilical vein endothelial cells. Atherosclerosis. 2007;190(1):90-9.
32. Huerta-Garcia E, Ventura-Gallegos JL, Victoriano ME, Montiel-Davalos A, Tinoco-Jaramillo G, Lopez-Marure R. Dehydroepiandrosterone inhibits the activation and dysfunction of endothelial cells induced by high glucose concentration. Steroids. 2012;77(3):233-40.
33. Altman R, Motton DD, Kota RS, Rutledge JC. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vascul Pharmacol. 2008;48(2-3):76-84.
34. Zapata E, Ventura JL, De la Cruz K, Rodriguez E, Damian P, Masso F, et al. Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen-and estrogen-receptor independent. FEBS J. 2005;272(6):1343-53.
35. Nheu L, Nazareth L, Xu GY, Xiao FY, Luo RZ, Komesaroff P, et al. Physiological effects of androgens on human vascular endothelial and smooth muscle cells in culture. Steroids. 2011;76(14):1590-6.
36. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids. 2004;69(4):279-89.
37. Bhuiyan MS, Tagashira H, Fukunaga K. Dehydroepiandrosterone-mediated stimulation of sigma-1 receptor activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding. Cardiovasc Ther. 2011;29(4):219-30.
38. Gupte SA, Li KX, Okada T, Sato K, Oka M. Inhibitors of pentose phosphate pathway cause vasodilation: involvement of voltage-gated potassium channels. J Pharmacol Exp Ther. 2002;301(1):299-305.
39. Oka M, Karoor V, Homma N, Nagaoka T, Sakao E, Golembeski SM, et al. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc Res. 2007;74(3):377-87.
40. Chevalier M, Gilbert G, Lory P, Marthan R, Quignard JF, Savineau JP. Dehydroepiandrosterone (DHEA) inhibits voltage-gated T-type calcium channels. Biochem Pharmacol. 2012;83(11):1530-9.
41. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2011;301(5):H1798-809.
42. Nakamura S, Yoshimura M, Nakayama M, Ito T, Mizuno Y, Harada E, et al. Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation. 2004;110(13):1787-93.
43. Mannic T, Mouffok M, Python M, Yoshida T, Maturana AD, Vuilreceptor-induced chronotropic and hypertrophic actions in isolated rat cardiomyocytes. Endocrinology. 2013;154(3):1271-81.
44. Munoz YC, Gomez GI, Moreno M, Solis CL, Valladares LE, Velarde V. Dehydroepiandrosterone prevents the aggregation of platelets obtained from postmenopausal women with type 2 diabetes mellitus through the activation of the PKC/eNOS/NO pathway. Horm Metab Res. 2012;44(8):625-31.
45. Gupte SA, Tateyama M, Okada T, Oka M, Ochi R. Epiandrosterone, a metabolite of testosterone precursor, blocks L-type calcium channels of ventricular myocytes and inhibits myocardial contractility. J Mol Cell Cardiol. 2002;34(6):679-88.